

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : <b>C07D 211/26, A61K 31/405</b>	<b>A1</b>	(11) International Publication Number: <b>WO 94/22825</b> (43) International Publication Date: <b>13 October 1994 (13.10.94)</b>
<p>(21) International Application Number: <b>PCT/US94/03400</b></p> <p>(22) International Filing Date: <b>29 March 1994 (29.03.94)</b></p> <p>(30) Priority Data: 042.963      5 April 1993 (05.04.93)      <b>US</b></p> <p>(60) Parent Application or Grant (63) Related by Continuation US      042.963 (CON) Filed on      5 April 1993 (05.04.93)</p> <p>(71) Applicant (for all designated States except US): <b>MERCK &amp; CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).</b></p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): <b>CLAREMON, David, A. [US/US]; 1508 Aidenn Lair Road, Maple Glen, PA 19002 (US). LIVERTON, Nigel [GB/US]; 786 Sharon Lane, Harleysville, PA 19438 (US).</b></p> <p>(74) Agent: <b>PARR, Richard, S.; Merck &amp; Co., Inc., Patent Dept., 126 East Lincoln Avenue, Rahway, NJ 07065 (US).</b></p>	<p>(81) Designated States: <b>AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TT, UA, US, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</b></p> <p><b>Published</b> <i>With international search report.</i></p>	

(54) Title: **FIBRINOGEN RECEPTOR ANTAGONISTS**



(57) Abstract

Fibrinogen receptor antagonists of formula (I) are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets, for example (A).

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

TITLE OF THE INVENTION  
FIBRINOGEN RECEPTOR ANTAGONISTS

FIELD OF THE INVENTION

5           This invention relates to the discovery of fibrinogen receptor antagonists of Formula I for use in inhibiting the binding of fibrinogen to blood platelets and inhibiting the aggregation of blood platelets when administered to mammals, preferably humans.

10           BACKGROUND OF THE INVENTION

          The interaction of platelets with the coagulation and fibrinolytic systems in the maintenance of hemostasis may become pathogenic, requiring prevention and treatment. The fibrinogen receptor antagonists of Formula I are useful in treating various diseases related to  
15           platelet aggregation and fibrin formation.

          An interest in platelet inhibitors has reemerged as a result of a better understanding of the role of platelets and thrombosis in the pathogenesis of vascular disease, including unstable angina, acute myocardial infarction and stroke.

20           Platelets are cell-like anucleated fragments, found in the blood of all mammals which participate in blood coagulation. Fibrinogen is a glycoprotein present as a normal component of blood plasma. Fibrinogen participates in platelet aggregation and fibrin formation in the blood clotting mechanism. Platelets are deposited at sites of vascular  
25           injury where multiple physiological agonists act to initiate platelet aggregation culminating in the formation of a platelet plug to minimize blood loss. If the platelet plug occurs in the lumen of a blood vessel, normal blood flow is impaired.

30           Platelet membrane receptors are essential in the process of platelet adhesion and aggregation. Interaction of fibrinogen with a receptor on the platelet membrane complex IIb/IIIa is known to be essential for normal platelet function.

          Zimmerman *et al.*, U.S. Patent No. 4,683,291, describes peptides having utility in the study of fibrinogen-platelet, platelet-platelet,

- 2 -

and cell-cell interactions. The peptides are described as having utility where it is desirable to retard or prevent formation of a thrombus or clot in the blood. The general formula for the peptides includes an Arg-Gly-Asp sequence.

5 Tjoeng et al., EP 352,249, describe platelet aggregation inhibitors which antagonize interactions between fibrinogen and/or extracellular matrix proteins and the platelet gpIIb/IIIa receptor, including 8-guanido-octanoyl-Asp-2-(4-methoxyphenyl)ethyl amide.

10 Alig et al., EP 372,486, describe N-aryl beta-amino acids which inhibit fibrinogen, fibronectin and von Willebrand factor to the blood platelet fibrinogen receptor (glycoprotein IIb/IIIa).

15 Alig et al., EP 381,033, describe di-aryl or heteroaryl substituted alkanoic acid derivatives of a defined formula which inhibit binding of proteins to their specific receptors on cell surfaces, including fibrinogen.

Alig et al., EP 384,362, describe glycine peptides of a specified formula containing an amidine group which inhibit binding of fibrinogen to platelet fibrinogen receptors.

20 Horwell et al., EP 405,537, describe N-substituted cycloalkyl and polycycloalkyl alpha-substituted Trp-Phe- and phenethylamine derivatives which are useful for treating obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics.

25 It is an object of the present invention to provide fibrinogen receptor antagonists for use in inhibiting the binding of fibrinogen to blood platelets and inhibiting the aggregation of blood platelets. Another aspect of the present invention is to provide novel fibrinogen receptor antagonist compounds. Other objects of the present invention are to provide methods of inhibiting the binding of fibrinogen to blood platelets and inhibiting the aggregation of blood platelets, through the  
30 administration of novel fibrinogen receptor antagonist compounds. The above and other objects are accomplished by the present invention in the manner described below.


- 3 -

SUMMARY OF THE INVENTION

The present invention provides fibrinogen receptor antagonist compounds of the formula:


5

10



15 wherein G is

20




for use in inhibiting the binding of fibrinogen to blood platelets and for  
 25 inhibiting the aggregation of blood platelets. The above-mentioned  
 compounds can be used in a method of acting upon a fibrinogen receptor  
 which comprises administering a therapeutically effective but non-toxic  
 amount of such compound to a mammal, preferably a human. A  
 pharmaceutical composition comprising a pharmaceutically acceptable  
 30 carrier and, dispersed therein, an effective but non-toxic amount of such  
 compound is another feature of this invention.


- 4 -

DETAILED DESCRIPTION OF THE INVENTION

Fibrinogen receptor antagonist compounds of Formula I are useful in a method of inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets. Fibrinogen receptor antagonists of this invention are illustrated by compounds having the formula:




wherein G is



A, B, C and D independently represent a carbon atom or a nitrogen atom;

X is



or a 4- to 10- membered mono- or polycyclic aromatic or nonaromatic ring system containing 0, 1, 2, 3 or 4

- 5 -

heteroatoms selected from N, O and S and either unsubstituted or substituted with R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> or R<sup>4</sup>, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are independently selected from the group consisting of hydrogen,  
5 C<sub>1</sub>-10 alkyl,  
aryl C<sub>0</sub>-8 alkyl,  
oxo,  
thio,  
10 amino C<sub>0</sub>-8 alkyl, C<sub>1</sub>-3 acylamino C<sub>0</sub>-8 alkyl,  
C<sub>1</sub>-6 alkylamino C<sub>0</sub>-8 alkyl,  
C<sub>1</sub>-6 dialkylamino C<sub>0</sub>-8 alkyl,  
C<sub>1</sub>-4 alkoxy C<sub>0</sub>-6 alkyl,  
carboxy C<sub>0</sub>-6 alkyl, C<sub>1</sub>-3 alkoxycarbonyl C<sub>0</sub>-6 alkyl,  
15 carboxy C<sub>0</sub>-6 alkyloxy,  
hydroxy C<sub>0</sub>-6 alkyl, and  
fused or nonfused heteroaryl C<sub>0</sub>-8 alkyl, wherein the heteroaryl group contains 1, 2, 3 or 4 heteroatoms N, O, or S;  
20 Y is C<sub>0</sub>-8 alkyl,  
C<sub>0</sub>-8 alkyl-NR<sup>3</sup>-CO-C<sub>0</sub>-8 alkyl,  
C<sub>0</sub>-8 alkyl-CONR<sup>3</sup>-C<sub>0</sub>-8 alkyl,  
C<sub>0</sub>-8 alkyl-O-C<sub>0</sub>-8 alkyl,  
C<sub>0</sub>-8 alkyl-S(O<sub>n</sub>)-C<sub>0</sub>-8 alkyl, or  
25 C<sub>0</sub>-8 alkyl-SO<sub>2</sub>-NR<sup>3</sup>-C<sub>0</sub>-8 alkyl-,  
C<sub>0</sub>-8 alkyl-NR<sup>3</sup>-SO<sub>2</sub>-C<sub>0</sub>-8 alkyl-, or  
C<sub>1</sub>-8 alkyl-CO-C<sub>0</sub>-8 alkyl;

30

- 6 -

Z is

 $-(CH_2)_m-$ ,  $-C\equiv C-CH_2-$  or $-C=C(CH_2)_m-$ 

5

 $\begin{array}{cc} | & | \\ H & H \end{array}$ 

wherein m is 0-6;

10 R<sup>5</sup> is

hydrogen,

C<sub>1-6</sub> alkyl,C<sub>0-6</sub> alkylcarboxy C<sub>0-6</sub> alkyl,C<sub>0-6</sub> alkyloxy C<sub>0-6</sub> alkyl,

15

hydroxy C<sub>0-6</sub> alkyl,aryl C<sub>0-6</sub> alkyl, or

halogen;

R<sup>6</sup> is

20

hydrogen,

C<sub>1-8</sub> alkyl,aryl C<sub>0-6</sub> alkyl,C<sub>3-8</sub> cycloalkyl C<sub>0-6</sub> alkyl,C<sub>0-6</sub> alkylcarboxy C<sub>0-6</sub> alkyl, carboxy C<sub>0-6</sub> alkyl,

25

C<sub>1-4</sub> alkyloxy C<sub>0-6</sub> alkyl, orhydroxy C<sub>0-6</sub> alkyl, provided that

any of which groups may be substituted or

unsubstituted independently with R<sup>1</sup> or R<sup>2</sup>, and providedthat, when two R<sup>6</sup> groups are attached to the same carbon,

30

they may be the same or different;



- 7 -

R<sup>7</sup> is

5 hydrogen, fluorine,  
C<sub>1-8</sub> alkyl,  
C<sub>3-8</sub> cycloalkyl,  
aryl C<sub>0-6</sub> alkyl,  
C<sub>0-6</sub> alkylamino C<sub>0-6</sub> alkyl,  
C<sub>0-6</sub> dialkylamino C<sub>0-6</sub> alkyl,  
C<sub>1-8</sub> alkylsulfonylamino C<sub>0-6</sub> alkyl,  
10 aryl C<sub>0-6</sub> alkylsulfonylamino C<sub>0-6</sub> alkyl,  
C<sub>1-8</sub> alkyloxycarbonylamino C<sub>0-8</sub>-alkyl,  
aryl C<sub>0-8</sub> alkyloxycarbonylamino C<sub>0-8</sub> alkyl,  
C<sub>1-8</sub> alkylcarbonylamino C<sub>0-6</sub> alkyl,  
aryl C<sub>0-6</sub> alkylcarbonylamino C<sub>0-6</sub> alkyl,  
15 C<sub>0-8</sub> alkylaminocarbonylamino C<sub>0-6</sub> alkyl,  
aryl C<sub>0-8</sub> alkylaminocarbonylamino C<sub>0-6</sub> alkyl,  
C<sub>1-6</sub> alkylsulfonyl C<sub>0-6</sub> alkyl,  
aryl C<sub>0-6</sub> alkylsulfonyl C<sub>0-6</sub> alkyl,  
C<sub>1-6</sub> alkylcarbonyl C<sub>0-6</sub> alkyl,  
20 aryl C<sub>0-6</sub> alkylcarbonyl C<sub>0-6</sub> alkyl,  
C<sub>1-6</sub> alkylthiocarbonylamino C<sub>0-6</sub> alkyl, or aryl C<sub>0-6</sub>  
alkylthiocarbonylamino C<sub>0-6</sub> alkyl wherein groups may be  
unsubstituted or substituted with one or more substituents  
selected from R<sup>1</sup> and R<sup>2</sup>, and provided that when two R<sup>7</sup>  
25 groups are attached to the same carbon atom, they may be  
the same or different;

R<sup>8</sup> is

30 hydroxy,  
C<sub>1-8</sub> alkyloxy,  
aryl C<sub>0-6</sub> alkyloxy,  
C<sub>1-8</sub> alkylcarbonyloxy C<sub>1-4</sub> alkyloxy,  
aryl C<sub>1-8</sub> alkylcarbonyloxy C<sub>1-4</sub> alkyloxy, or

- 8 -

an L- or D-amino acid joined by an amide linkage and wherein the carboxylic acid moiety of said amino acid is as the free acid or is esterified by C<sub>1</sub>-6 alkyl; and

R<sup>9</sup> is

hydrogen, C<sub>1</sub>-8 alkyl, or -W-V, wherein W is C<sub>1</sub>-3 alkyl and V is 5- to 7-membered monocyclic aromatic or nonaromatic ring system containing 0, 1, 2, 3 or 4 heteroatoms selected from N, O and S.


When substituent R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> or Y includes the definition C<sub>0</sub>, (e.g. aryl C<sub>0</sub> alkyl), the group modified by C<sub>0</sub> is not present in the substituent.

"Aryl" means a mono- or polycyclic system composed of 5- and 6- membered aromatic rings containing 0, 1, 2, 3 or 4 heteroatoms chosen from N, O or S and either unsubstituted or substituted with R<sup>1</sup>.

"Alkyl" means straight or branched chain alkane, alkene or alkyne.

"Halogen" includes fluorine, chlorine, iodine and bromine.

A preferred embodiment of the present invention is



wherein:

X is

-NR<sup>1</sup>R<sup>2</sup> or a 4- to 10-membered mono- or polycyclic aromatic or non-aromatic ring system containing 0, 1 or 2

- 9 -

heteroatoms chosen from N or O and either unsubstituted or substituted with R<sup>1</sup> and R<sup>2</sup>, wherein R<sup>1</sup> and R<sup>2</sup> are independently chosen from:

5 hydrogen,  
C<sub>1-6</sub> alkyl,  
aryl C<sub>0-6</sub> alkyl,  
carboxy C<sub>0-6</sub> alkyl,  
hydroxy C<sub>0-6</sub> alkyl,  
10 C<sub>1-3</sub> alkyloxy C<sub>0-6</sub> alkyl, or  
amino C<sub>0-6</sub> alkyl;

Y is

15 C<sub>0-6</sub> alkyl,  
C<sub>1-6</sub> alkyl-CO-C<sub>0-6</sub> alkyl, or  
C<sub>0-6</sub> alkyl-NR<sup>3</sup>-CO-C<sub>0-6</sub> alkyl, wherein  
R<sup>3</sup> is hydrogen,  
C<sub>1-6</sub> alkyl,  
aryl C<sub>0-6</sub> alkyl,  
20 carboxy C<sub>0-6</sub> alkyl,  
hydroxy C<sub>0-6</sub> alkyl,  
C<sub>1-3</sub> alkyloxy C<sub>0-6</sub> alkyl, or  
amino C<sub>0-6</sub> alkyl;

25 Z is

$-(CH_2)_m-$ , or  $-C \equiv C-CH_2-$  ;

wherein m is 0-6;

30 R<sup>3</sup> is

hydrogen,  
C<sub>1-6</sub> alkyl,  
aryl C<sub>0-6</sub> alkyl,  
carboxy C<sub>0-6</sub> alkyl,

- 10 -

hydroxy C0-6 alkyl,  
C1-3 alkyloxy C0-6 alkyl, or  
amino C0-6 alkyl;

5 R<sup>7</sup> is

hydrogen, fluorine,  
C1-8 alkyl,  
C3-8 cycloalkyl,  
10 aryl C0-6 alkyl,  
C0-6 alkylamino C0-6 alkyl,  
C0-6 dialkylamino C0-6 alkyl,  
C1-8 alkylsulfonylamino C0-6 alkyl,  
aryl C0-6 alkylsulfonylamino C0-6 alkyl,  
15 C1-8 alkyloxycarbonylamino C0-8 alkyl,  
aryl C0-8 alkyloxycarbonylamino C0-8 alkyl,  
C1-8 alkylcarbonylamino C0-6 alkyl,  
aryl C0-6 alkylcarbonylamino C0-6 alkyl,  
C0-8 alkylaminocarbonylamino C0-6 alkyl,  
20 aryl C0-8 alkylaminocarbonylamino C0-6 alkyl,  
C1-6 alkylsulfonyl C0-6 alkyl,  
aryl C0-6 alkylsulfonyl C0-6 alkyl,  
C1-6 alkylcarbonyl C0-6 alkyl,  
aryl C0-6 alkylcarbonyl C0-6 alkyl,  
25 C1-6 alkylthiocarbonylamino C0-6 alkyl, or  
aryl C0-6 alkylthiocarbonylamino C0-6 alkyl wherein  
groups may be unsubstituted or substituted with one or more  
substituents selected from R<sup>1</sup> and R<sup>2</sup>, and provided that  
when two R<sup>7</sup> groups are attached to the same carbon atom,  
30 they may be the same or different;

R<sup>8</sup> is

hydroxy,  
C1-6 alkyloxy,  
aryl C1-4 alkyloxy, or

- 11 -

C<sub>1</sub>-6 alkylcarbonyloxy C<sub>1</sub>-4 alkyloxy; and

R<sup>9</sup> is


5

C<sub>1</sub>-3 alkyl or -W-V, wherein W is C<sub>1</sub>-3 alkyl and V is 6-membered monocyclic aromatic ring system containing 0, 1, 2, 3 or 4 heteroatoms selected from N, O and S.

A more preferred embodiment of the present invention is

10

15



wherein:

20 X is

25

-NR<sup>1</sup>R<sup>2</sup> or a 4- to 10-membered mono- or polycyclic aromatic or non-aromatic ring system containing 0, 1 or 2 heteroatoms chosen from N or O and either unsubstituted or substituted with R<sup>1</sup> and R<sup>2</sup>, wherein R<sup>1</sup> and R<sup>2</sup> are independently chosen from:

30

hydrogen,  
C<sub>1</sub>-6 alkyl,  
aryl C<sub>0</sub>-6 alkyl,  
carboxy C<sub>0</sub>-6 alkyl,  
hydroxy C<sub>0</sub>-6 alkyl,  
C<sub>1</sub>-3 alkyloxy C<sub>0</sub>-6 alkyl, or  
amino C<sub>0</sub>-6 alkyl;

Y is

C<sub>0</sub>-6 alkyl,

- 12 -

C1-6 alkyl-CO-C0-6 alkyl, or  
C0-6 alkyl-NR<sup>3</sup>-CO-C0-6 alkyl wherein  
R<sup>3</sup> is hydrogen,  
C1-6 alkyl,  
5 aryl C0-6 alkyl,  
carboxy C0-6 alkyl,  
hydroxy C0-6 alkyl,  
C1-3 alkyloxy C0-6 alkyl, or  
10 amino C0-6 alkyl;

Z is

-(CH<sub>2</sub>)<sub>m</sub>-, or -C≡C-CH<sub>2</sub>-;

wherein m is 0-3;

R<sup>3</sup> is

hydrogen,  
C1-6 alkyl,  
15 aryl C0-6 alkyl,  
carboxy C0-6 alkyl,  
hydroxy C0-6 alkyl,  
C1-3 alkyloxy C0-6 alkyl, or  
20 amino C0-6 alkyl;

R<sup>7</sup> is

hydrogen, fluorine,  
C1-8 alkyl,  
C3-8 cycloalkyl,  
C0-6 alkylamino C0-6 alkyl,  
30 C0-6 dialkylamino C0-6 alkyl,  
C1-8 alkylsulfonylamino C0-6 alkyl, or  
C1-8 alkylcarbonylamino C0-6 alkyl,  
wherein groups may be unsubstituted or substituted with one  
or more substituents selected from R<sup>1</sup> and R<sup>2</sup>, and provided

- 13 -

that when two R<sup>7</sup> groups are attached to the same carbon atom, they may be the same or different;

5 R<sup>8</sup> is


hydroxy,  
C<sub>1-6</sub> alkyloxy,  
aryl C<sub>1-4</sub> alkyloxy, or  
C<sub>1-6</sub> alkylcarbonyloxy C<sub>1-4</sub> alkyloxy; and

10 R<sup>9</sup> is

methyl or methylphenyl.

Especially preferred compounds of the invention are:

15




25


30

- 14 -


5



10



15



20 The portion of certain structures represented by  
 " —  $\equiv$  — ", which appears above and throughout the application,  
 means " —  $C \equiv C$  — ".

An ADP-stimulated platelet aggregation assay was used to determine inhibition associated with compounds of the invention.

25 Human platelets were isolated from fresh blood, collected into acid citrate/dextrose by differential centrifugation followed by gel filtration on Sepharose 2B in divalent ion-free Tyrode's buffer (pH 7.4) containing 2% bovine serum albumin. Platelet aggregation was measured at 37°C in a Chronolog aggregometer. The reaction mixture contained gel-filtered human platelets ( $2 \times 10^8$  per ml), fibrinogen (100  $\mu$ g/ml),  
 30  $Ca^{2+}$  (1 mM), and the compound to be tested. Aggregation was initiated by adding 10  $\mu$ M ADP 1 minute after the other components had been added. The reaction was allowed to proceed for at least 2 minutes. The extent of inhibition of aggregation was expressed as the percentage of the rate of aggregation observed in the absence of inhibitor. The  $IC_{50}$  is the



- 15 -

dose of a particular compound inhibiting aggregation by 50% relative to a control lacking the compound.

The abbreviations listed below are defined as Bn, benzyl; NMM, N-methylmorpholine; HOBt, 1-hydroxybenzotriazole; EDC, 1-(3-  
5 dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; DMF, dimethylformamide; Pib, 4-(4-piperidyl)butanoyl; pTSA, paratoluene-sulfonic acid; DMS, dimethylsulfide; TFA, trifluoroacetic acid; THF, tetrahydrofuran; DIBAL, diisobutylaluminumhydride; Boc (or BOC), tert-butoxycarbonyl; Cbz, benzyloxycarbonyl; Suc, succinoyl; alpine  
10 borane,  $\beta$ -isopinocampheyl-9-borabicyclo[3.3.1]-nonane; TBDMS, tert-butyldimethylsilyl; Jones reagent, chromic acid; NBS, N-Bromo-succinimide; BPO, Benzoyl peroxide; PPh<sub>3</sub>, triphenyl phosphine; DMSO, Dimethylsulfoxide; Et<sub>3</sub>N, triethylamine; Tf<sub>2</sub>O, triflicanhydride; DMAP, 4-dimethylaminopyridine; BOP, benzotriazol-1 yloxytris-  
15 (dimethylamino)-phosphonium hexafluorophosphate; PhCHO, benzaldehyde; and Boc<sub>2</sub>O, di-t-butylidicarbonate; dppp, 1,3-bis(diphenylphosphino)propane; ETOH, ethyl acetate; CH<sub>2</sub>Cl<sub>2</sub>, methylene chloride; HOAc, acetic acid; CH<sub>3</sub>OH, methanol; CHCl<sub>3</sub>,  
20 chloroform.

Unless otherwise indicated, all degree values are Celsius.

The pharmaceutically acceptable salts of the compounds of Formula I include the conventional non-toxic salts or the quaternary ammonium salts of the compounds of Formula I formed, e.g., from non-  
25 toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic,  
30 maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

The pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of Formula I which contain a basic or acidic moiety by conventional chemical methods.

- 16 -

Generally, the salts are prepared by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.

5           The pharmaceutically acceptable salts of the acids of Formula I are also readily prepared by conventional procedures such as treating an acid of Formula I with an appropriate amount of a base, such as an alkali or alkaline earth metal hydroxide e.g. sodium, potassium, lithium, calcium, or magnesium, or an organic base such as an amine,  
10 e.g., dibenzylethylene-diamine, trimethylamine, piperidine, pyrrolidine, benzylamine and the like, or a quaternary ammonium hydroxide such as tetramethylammonium hydroxide and the like.

          The compounds of Formula I are useful in inhibiting the binding of fibrinogen to blood platelets, inhibiting aggregation of blood  
15 platelets, treatment of thrombus formation or embolus formation, and in the prevention of thrombus formation or embolus formation. These compounds are useful as pharmaceutical agents for mammals, especially for humans. The compounds of this invention may be administered to patients where prevention of thrombosis by inhibiting binding of  
20 fibrinogen to the platelet membrane glycoprotein complex IIb/IIIa receptor is desired. Compounds of this invention may also be used to prevent or modulate the progress of myocardial infarction, unstable angina and thrombotic stroke, in either acute or chronic settings. In addition, they may be useful in surgery on peripheral arteries (arterial  
25 grafts, carotid endarterectomy) and in cardiovascular surgery where manipulation of arteries and organs, and/or the interaction of platelets with artificial surfaces, leads to platelet aggregation and consumption. The aggregated platelets may form thrombi and thromboemboli. Compounds of this invention may be administered to surgical patients to  
30 prevent the formation of thrombi and thromboemboli.

          Extracorporeal circulation is routinely used for cardiovascular surgery in order to oxygenate blood. Platelets adhere to surfaces of the extracorporeal circuit. Adhesion is dependent on the interaction between GPIIb/IIIa on the platelet membranes and fibrinogen

- 17 -

adsorbed to the surface of the circuit. (Glusko et al., Amer. J. Physiol., 1987, 252:H, pp 615-621). Platelets released from artificial surfaces show impaired hemostatic function. Compounds of this invention may be administered to prevent adhesion.

5 Other applications of these compounds include prevention of platelet thrombosis, thromboembolism, reocclusion, and restenosis during and after thrombolytic therapy and prevention of platelet thrombosis, thromboembolism, reocclusion and restenosis after angioplasty of coronary and other arteries and after coronary artery bypass procedures.

10 The compounds of Formula I may be administered to mammals, preferably in combination with pharmaceutically acceptable carriers or diluents, optionally with known adjuvants such as alum, in a pharmaceutical composition which is non-toxic and in a therapeutically effective amount, according to standard pharmaceutical practice. The  
15 compounds can be administered orally or parenterally, including intravenous, intramuscular, intraperitoneal, trans-dermal, subcutaneous and topical administration.

For oral use of a fibrinogen receptor antagonist according to this invention, the selected compounds may be administered, for  
20 example, in the form of tablets or capsules, or as an aqueous solution or suspension. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch, and lubricating agents, such as magnesium stearate, are commonly added. For oral  
25 administration in capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents may be added.

For intramuscular, intraperitoneal, subcutaneous, and  
30 intravenous use, sterile solutions of the active ingredient are usually prepared, and the pH of the solutions should be suitably adjusted and buffered. For intravenous use, the total concentration of solutes should be controlled in order to render the preparation isotonic.

The present invention also encompasses a pharmaceutical composition useful in the treatment and prevention of diseases related to

- 18 -

platelet aggregation, fibrin formation, and thrombus and embolus formation, comprising the administration of a therapeutically effective but non-toxic amount of the compounds of Formula I, with or without pharmaceutically acceptable carriers or diluents.

5           Compositions of this invention include fibrinogen receptor antagonist compounds of this invention in combination with pharmacologically acceptable carriers, e.g. saline, at a pH level e.g. 7.4, suitable for achieving inhibition of platelet aggregation. The compositions may also be combined with anticoagulants such as heparin  
10 or warfarin. The compositions may also be combined with thrombolytic agents such as plasminogen activators or streptokinase in order to inhibit platelet aggregation in more acute settings. The composition may further be combined with antiplatelet agents such as aspirin. The compositions  
15 are soluble in an aqueous medium, and may therefore be effectively administered in solution.

          When a compound according to Formula I is used as a fibrinogen receptor antagonist in a human subject, the daily dosage will normally be determined by the prescribing physician with the dosage  
20 generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patients symptoms.

          In one exemplary application, a suitable amount of compound is administered orally to a heart attack victim subsequent to angioplasty. Administration occurs subsequent to angioplasty, and is in  
25 an amount sufficient to inhibit platelet aggregation, e.g. an amount which achieves a steady state plasma concentration of between about 0.01-50 mM preferably between about 0.01-10 mM.

          The present invention also includes a pharmaceutical composition comprising compounds of the present invention in combination with tissue type plasminogen activator or streptokinase. The  
30 invention also includes a method for promoting thrombolysis and preventing reocclusion in a patient which comprises administering to the patient an effective amount of compositions of the invention.

          The present invention provides a method of inhibiting the binding of fibrinogen to blood platelets, inhibiting aggregation of blood

- 19 -


platelets, treating thrombus formation or embolus formation, and in preventing thrombus formation or embolus formation in a mammal, comprising the administration of a therapeutically effective but non-toxic amount of the compounds of this invention, with or without  
5 pharmaceutically acceptable carriers or diluents.

The present invention still further provides a method of inhibiting the binding of fibrinogen to blood platelets, inhibiting aggregation of blood platelets, treating thrombus formation or embolus formation, and in preventing thrombus formation or embolus formation in  
10 a mammal, comprising the administration of a therapeutically effective but non-toxic amounts of the compounds of this invention in combination with thrombolytic agents, such as tissue plasminogen activators or streptokinase, anticoagulants such as heparin or warfarin, or antiplatelet agents such as aspirin, with or without pharmaceutically acceptable  
15 carriers or diluents.

The compounds of Formula I are prepared according to the reaction schemes set forth below.

### EXAMPLE 1

#### Preparation of Boc-4-Piperidine-2-ethanol (1-5)



4-Piperidine-2-ethanol (Aldrich) (130 g, 1.0 mole) was dissolved in 700 mL dioxane, cooled to 0°C and treated with 3 N NaOH (336 mL, 1.0 mole), and di-t-butyldicarbonate (221.8 g, 1.0 mole). The  
30 ice bath was removed and the reaction stirred overnight. The reaction was concentrated, diluted with water and extracted with ether. The ether layers were combined, washed with brine, dried over MgSO<sub>4</sub>, filtered and evaporated to give 1-5 R<sub>f</sub> = 0.37 in 1:1 EtOAc/Hexanes, ninhydrin stain.


- 20 -

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>) δ 4.07 (bs, 2H), 3.7 (bs, 2H), 2.7 (t, J = 12.5 Hz, 2H), 1.8-1.6 (m, 6H), 1.51 (s, 9H), 1.1 (ddd, J = 4.3, 12.5, 12 Hz, 2H).

5 Boc-4-piperidine-2-ethyl iodide (1-6)

Boc-4-piperidine-2-ethanol (1-5) (10.42 g, 0.048 mole) was dissolved in 400 ml benzene and imidazole (4.66 g, 0.068 moles) and triphenylphosphine (15.24 g, 0.05 moles) were added at room temperature. After 6 hours the reaction mixture was filtered and the  
10 filtrate was evaporated to give a dark residue. This was purified by flash chromatography on silica gel eluting with 10% EtOAc-hexanes to give 1-6 as a yellow oil.

15 EXAMPLE 2



2-3

20

4-(N-t-Butyloxycarbonylpiperidinyl)methylamine (2-3)

A solution of 4-(piperidinyl)methylamine (22.8 g, 0.2 mmoles) in toluene (250 ml) was treated with benzaldehyde (21.2 g, 0.2 mmoles) at room temperature and the resulting mixture was heated at  
25 reflux for 3 hours with the aid of a Dean-Stark trap for water removal. The cooled reaction mixture containing the desired Schiff's base was treated portionwise with di-t-butyl dicarbonate (47.96 g, 0.22 moles) and the resulting solution was stirred at room temperature for 16 hours. The solvent was then removed and the residue was cooled to 0-5°C and  
30 treated with 1N KHSO<sub>4</sub> (220 ml) with stirring for 3 hours. The resulting reaction mixture was extracted with ether (3 x 200 ml) and then made basic with 1N KOH solution and extracted with CHCl<sub>3</sub> (4 x 75 ml). The combined organic extract was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>) filtered through celite, and the solvent removed to provide pure 2-3 as a clear oil.


- 21 -

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.13 (2H, m), 1.45 (9H, s), 1.60 (1H, m), 1.74 (2H, d), 2.68 (4H, m), 4.15 (2H, bd).

EXAMPLE 3

5

10


2-(Butanesulfonylamino)pent-4-ynoic acid, ethyl ester (3-1)

A solution of propargylglycine ethyl ester hydrochloride (from treatment of 2.0 g (17.7 mmol) of propargylglycine with EtOH/HCl at reflux) in CH<sub>2</sub>Cl<sub>2</sub> (30 ml) and 10 ml (57 mmol) diisopropylethylamine was cooled to 0°C and 35 ml of butanesulfonyl chloride added dropwise. After 30 minutes, the reaction mixture was poured into cold 10% citric acid solution and extracted with ether. The organic phase was washed with NaHCO<sub>3</sub> solution, brine and dried (MgSO<sub>4</sub>). The crude product was purified by flash column chromatography to afford 2.6 g of 3-1. NMR (300 MHz, CDCl<sub>3</sub>): 5.12 (d, 1H), 4.27 (m, 3H), 3.06 (m, 2H), 2.68 (m, 2H), 2.09 (t, 1H), 1.83 (m, 2H), 1.45 (m, 2H), 1.31 (t, 3H), 0.95 (t, 1H).

25

30


- 22 -

EXAMPLE 4




- 23 -

5

4-3

10

15

4-1

20


N-Benzyl-2-[(N-Boc-piperidin-4-yl)ethyl]-glycine, ethyl ester (4-1)

A solution of glycine benzaldehyde imine (10.2 g, 53 mmol) in 100 ml of THF was added dropwise to a cooled (-78°C) and stirred solution of potassium t-butoxide (5.8 g, 52 mmol) in 300 ml THF over 20 min. After 15 min. a solution of Boc-4-(2-iodoethyl) piperidine (1-6) (18.2 g, 52 mmol) was added and stirring continued at -78°C for 2 h. followed by standing at -20°C for 18 h. After stirring 2 h. at r.t., the reaction mixture was concentrated to 50% of volume, poured into ice cold saturated NH<sub>4</sub>Cl and extracted with ether. The organic phase was washed with brine, dried (MgSO<sub>4</sub>) and the solvent evaporated. 1 g of the resulting oil was dissolved in 10 ml of methanol, cooled to 0°C and 100 mg of sodium borohydride added in portions over 5 mins. After an additional 10 min., the reaction was concentrated, poured into water and extracted with ether. The organic extracts were washed with brine, dried

- 24 -

(MgSO<sub>4</sub>) and solvent evaporated to give crude product purified by flash column chromatography (5:1 → 2:1 hexane:EtOAc) to afford 410 mg of 4-1.


5 NMR (300 MHz, CDCl<sub>3</sub>) δ 7.2-7.4 (m, 5H), 4.17 (g, 2H), 4.05 (brs, 2H), 3.80 (d, 1/2 of AB, 1H), 3 and 2 (d, 1/2 of AB, 1H), 3.22 (t, 1H), 2.63 (brt, 2H), 0.95-1.9 (m, 22H).

4-2

7-Iodo-4-benzyl-3-[2-(N-Boc-piperidin-4-yl)ethyl]-1H-1,4-dioxo-benzodiazepine (4-2)

A mixture of 4-iodoisatoic anhydride (3.5 g, 12.1 mmol) (Ann. Chim. (Rome) vol. 57, no. 6 (1967) pp. 607-615) and amino ester 4-1 (5.0 g, 12.3 mmol) in 35 ml of pyridine was heated to reflux for 40 h. The solvent was evaporated and the residue purified by flash chromatography (EtOAc → 20% EtOH/EtOAc) to afford 4.0 g of 4-2 as a foam.

25 NMR (300 MHz, CD<sub>3</sub>OD) 8.4 (brs, 1H), 7.85 (d, 1H), 6.95-7.5 (m, 6H), 4.45-4.8 (m, 2H), 3.9-4.3 (m, 3H), 2.6 (brs, 2H), 0.7-2.0 (m, 18H).

4-3

- 25 -


2-Butanesulfonylamino-5-[4-benzyl-3-(2-[piperidin-4-yl]ethyl)-1H-1,4-dioxobenzodiazepin-7-yl]pentanoic acid, trifluoroacetate salt (4-3)

5 A mixture of iodide (975 mg, 1.61 mmol), acetylene (3-1), (500 mg, 1.91 mmol), bis(triphenylphosphine) palladium (II) chloride (80 mg, 0.11 mmol) and copper (I) iodide (40 mg, 0.21 mmol) in diethylamine (12 ml) was stirred in the dark at room temperature for 3 hours, under argon. The volatiles were evaporated and the residue  
10 partitioned between 10% citric acid solution and ethyl acetate. The organic phase was washed with water, saturated NaHCO<sub>3</sub>, brine and dried (MgSO<sub>4</sub>). The solvent was evaporated to give 930 mg of a yellow foam.

15 150 mg of this was dissolved in 25 ml of EtOAc and hydrogenated at 50 psi over 10% palladium charcoal, for 18 hours to give, after filtration and evaporation, 150 mg of a gum. This was dissolved in THF (3 ml) and 1M NaOH (3 ml) added, followed by 1 ml methanol. The reaction mixture was stirred for 18 hours, concentrated and partitioned between EtOAc and water. The organic phase was  
20 washed with water and brine, dried (MgSO<sub>4</sub>) and the solvent evaporated to give a foam which partially dissolved in 3 ml of CH<sub>2</sub>Cl<sub>2</sub>. After cooling to -10°C, trifluoroacetic acid (3 ml) was added and stirring continued for 15 minutes before evaporation of volatiles. The resulting gum was purified by reverse phase preparative HPLC to give 4-3. M.S. (POS FAB) 657 (M<sup>+</sup>+CO<sub>2</sub>+1).  
25 NMR (300 MHz), 8.0 (d, 1H), 7.57 (d, 1H), 7.2-7.46 (m, 6H), 4.1-4.7 (m, 3H), 4.02 (dd, 1H), 3.02 (t, 2H), 2.7-2.95 (m, 4H), 1.65-2.0 (m, 10H), 1.1-1.5 (m, 7H), 0.94 (t, 3H).

30

- 26 -


EXAMPLE 55

2-Butanesulfonylamino-5-[4-benzyl-3-(2-[piperidin-4-yl]ethyl)-1H-1,4-dioxobenzodiazepin-7-yl]pent-4-ynoic acid, trifluoroacetate salt (5)

Iodide 4-2 was coupled with acetylene 3-1 and deprotected as described in 4-3 to provide 5. M.S. (POS FAB) 653 M<sup>++</sup>CO<sub>2</sub>+1.


	C	H	N
Analysis calculated for 1.8 CF <sub>3</sub> CO <sub>2</sub> H	52.53	5.18	6.88
Obs	52.58	5.14	6.81

- 27 -

EXAMPLE 6


- 28 -

5

6-3

10

15

6-1


20 N-Benzyl-N-Methyl-[2-(N-Boc-piperidin-4-yl)ethyl]glycine, ethyl ester (6-1)

Amine 4-1 (1.3 g, 3.2 mmol) was dissolved in 25 ml of methanol and 37% formaldehyde solution (0.3 mL) added, followed by 300 mg of sodium cyanoborohydride. The reaction mixture was stirred at  
25 r.t. overnight, poured into water and extracted with water and brine, dried (MgSO<sub>4</sub>) and the solvent evaporated to give 6-1.

NMR (300 MHz, CDCl<sub>3</sub>) 7.2-7.35 (m, 5H), 3.9-4.3 (m, 4H), 3.78 (1/2 of AB 1H), 3.57 (1/2 of AB 1H), 3.23 (t, 2H), 2.63 (brt, 2H), 2.26 (3 s, 3H), 1.6-1.8 (m, 5H), 1.44 (s, 9H), 1.31 (t, 3H), 1.0-1.4 (m, 4H).


30

- 29 -

6-2N-Benzyl-[2-(N-Boc-piperidin-4-yl)ethyl]glycine, ethyl ester (6-2)

A solution of amine 6-1 (1.2 g, 2.87 mmol) in 50 ml EtOH was hydrogenated at 50 psi over 100 mg of 10% palladium hydroxide on charcoal for 18h. The catalyst was removed by filtration and the filtrate


evaporated to give methylamine 6-2.  
NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  4.19 (q, 2H), 4.04 (brs, 2H), 3.1 (t, 1H), 2.69 (brt, 2H), 2.37 (s, 3H), 1.0-1.7 (m, 21H).

6-32-Butanesulfonylamino-5-[4-methyl-3-(2-piperidin-4-yl)ethyl]-1H, 1,4-dioxobenzodiazepin-7-yl]pentanoic acid, trifluoroacetate salt (6-3)

Using the same procedure as described for the preparation of 4, but replacing benzylamine 4-1 with methylamine 6-2 afforded 6-3.  
(saturated)

NMR (300 MHz, D<sub>2</sub>O)  $\delta$  7.76, (d, 1H), 7.40 (d, 1H), 7.23 (m, 1H), 4.22 (m, 1H), 3.82 (m, 1H), 3.22 (brd, 2H), 2.95 (t, 2H), 2.83 (s, 3H), 2.76 (m, 2H), 2.56 (m, 2H), 1.0-2.0 (m, 17H), 0.67 (t, 3H).

- 30 -

EXAMPLE 77

2-Butanesulfonylamino-5-[4-methyl-3-[2-(piperidin-4-yl)ethyl]-1H-1,4-dioxobenzodiazepin-7-yl]pent-4-ynoic acid, trifluoroacetate salt (7)

Utilizing the same scheme described for preparation of 5, but using methylamine 6-2 in place of benzylenene 4-1, afforded acetylene 7.


NMR (300 MHz, D<sub>2</sub>O)  $\delta$  7.93 (brs, 1H), 7.58 (d, 1H), 7.20 (m, 1H), 4.23 (brs, 1H), 4.16 (dd, 1H), 3.94 (q, 1H), 3.23 (brd, 2H), 3.04 (m, 2H), 2.6-2.9 (m, 8H), 0.95-2 (m, 17H), 0.59 (t, 3H).




- 31 -

WHAT IS CLAIMED IS:

1. A fibrinogen receptor antagonist of the following  
 5 formula:




15 wherein G is



25 A, B, C and D independently represent a carbon atom or a nitrogen atom;

X is



or a 4- to 10- membered mono- or polycyclic aromatic or nonaromatic ring system containing 0, 1, 2, 3 or 4 heteroatoms selected from N, O and S and either unsubstituted or substituted with R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> or R<sup>4</sup>, wherein

- 32 -


R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are independently selected from the group consisting of hydrogen,  
 C<sub>1</sub>-10 alkyl,  
 aryl C<sub>0</sub>-8 alkyl,  
 5       oxo,  
        thio,  
        amino C<sub>0</sub>-8 alkyl, C<sub>1</sub>-3 acylamino C<sub>0</sub>-8 alkyl,  
        C<sub>1</sub>-6 alkylamino C<sub>0</sub>-8 alkyl,  
 10       C<sub>1</sub>-6 dialkylamino C<sub>0</sub>-8 alkyl,  
        C<sub>1</sub>-4 alkoxy C<sub>0</sub>-6 alkyl,  
        carboxy C<sub>0</sub>-6 alkyl, C<sub>1</sub>-3 alkoxycarbonyl C<sub>0</sub>-6 alkyl,  
        carboxy C<sub>0</sub>-6 alkyloxy,  
        hydroxy C<sub>0</sub>-6 alkyl, and  
 15       fused or nonfused heteroaryl C<sub>0</sub>-8 alkyl, wherein the  
        heteroaryl group contains 1, 2, 3 or 4 heteroatoms N, O, or  
        S;

Y is       C<sub>0</sub>-8 alkyl,  
 20       C<sub>0</sub>-8 alkyl-NR<sup>3</sup>-CO-C<sub>0</sub>-8 alkyl,  
        C<sub>0</sub>-8 alkyl-CONR<sup>3</sup>-C<sub>0</sub>-8 alkyl,  
        C<sub>0</sub>-8 alkyl-O-C<sub>0</sub>-8 alkyl,  
        C<sub>0</sub>-8 alkyl-S(O<sub>n</sub>)-C<sub>0</sub>-8 alkyl, or  
        C<sub>0</sub>-8 alkyl-SO<sub>2</sub>-NR<sup>3</sup>-C<sub>0</sub>-8 alkyl-,  
 25       C<sub>0</sub>-8 alkyl-NR<sup>3</sup>-SO<sub>2</sub>-C<sub>0</sub>-8 alkyl-, or  
        C<sub>1</sub>-8 alkyl-CO-C<sub>0</sub>-8 alkyl;

Z is

-(CH<sub>2</sub>)<sub>m</sub>-, -C≡C-CH<sub>2</sub>-

30



wherein m is 0-6;

- 33 -

R<sup>5</sup> is

5

hydrogen,  
C<sub>1-6</sub> alkyl,  
C<sub>0-6</sub> alkylcarboxy C<sub>0-6</sub> alkyl,  
C<sub>0-6</sub> alkyloxy C<sub>0-6</sub> alkyl,  
hydroxy C<sub>0-6</sub> alkyl,  
aryl C<sub>0-6</sub> alkyl, or  
halogen;

10

R<sup>6</sup> is

15

hydrogen,  
C<sub>1-8</sub> alkyl,  
aryl C<sub>0-6</sub> alkyl,  
C<sub>3-8</sub> cycloalkyl C<sub>0-6</sub> alkyl,  
C<sub>0-6</sub> alkylcarboxy C<sub>0-6</sub> alkyl, carboxy C<sub>0-6</sub>  
alkyl,

20

C<sub>1-4</sub> alkyloxy C<sub>0-6</sub> alkyl, or  
hydroxy C<sub>0-6</sub> alkyl, provided that  
any of which groups may be substituted or  
unsubstituted independently with R<sup>1</sup> or R<sup>2</sup>, and provided  
that, when two R<sup>6</sup> groups are attached to the same carbon,  
they may be the same or different;

25

R<sup>7</sup> is

30

hydrogen, fluorine,  
C<sub>1-8</sub> alkyl,  
C<sub>3-8</sub> cycloalkyl,  
aryl C<sub>0-6</sub> alkyl,  
C<sub>0-6</sub> alkylamino C<sub>0-6</sub> alkyl,  
C<sub>0-6</sub> dialkylamino C<sub>0-6</sub> alkyl,  
C<sub>1-8</sub> alkylsulfonylamino C<sub>0-6</sub> alkyl,  
aryl C<sub>0-6</sub> alkylsulfonylamino C<sub>0-6</sub> alkyl,  
C<sub>1-8</sub> alkyloxycarbonylamino C<sub>0-8</sub> alkyl,  
aryl C<sub>0-8</sub> alkyloxycarbonylamino C<sub>0-8</sub> alkyl,

- 34 -

C1-8 alkylcarbonylamino C0-6 alkyl,  
 aryl C0-6 alkylcarbonylamino C0-6 alkyl,  
 C0-8 alkylaminocarbonylamino C0-6 alkyl,  
 aryl C0-8 alkylaminocarbonylamino C0-6 alkyl,  
 5 C1-6 alkylsulfonyl C0-6 alkyl,  
 aryl C0-6 alkylsulfonyl C0-6 alkyl,  
 C1-6 alkylcarbonyl C0-6 alkyl  
 aryl C0-6 alkylcarbonyl C0-6 alkyl,  
 10 C1-6 alkylthiocarbonylamino C0-6 alkyl, or  
 aryl C0-6 alkylthiocarbonylamino C0-6 alkyl wherein  
 groups may be unsubstituted or substituted with one or more  
 substituents selected from R<sup>1</sup> and R<sup>2</sup>, and provided that  
 when two R<sup>7</sup> groups are attached to the same carbon atom,  
 they may be the same or different;

15

R<sup>8</sup> is

hydroxy,  
 C1-8 alkyloxy,  
 aryl C0-6 alkyloxy,  
 20 C1-8 alkylcarbonyloxy C1-4 alkyloxy,  
 aryl C1-8 alkylcarbonyloxy C1-4 alkyloxy, or  
 an L- or D-amino acid joined by an amide linkage and  
 wherein the carboxylic acid moiety of said amino acid is as  
 the free acid or is esterified by C1-6 alkyl; and

25


R<sup>9</sup> is

hydrogen, C1-8 alkyl, or -W-V, wherein W is C1-3 alkyl and  
 V is 5- to 7-membered monocyclic aromatic or nonaromatic  
 ring system containing 0, 1, 2, 3 or 4 heteroatoms selected  
 from N, O and S.

30

2. A compound of Claim 1, having the formula

- 35 -



wherein:

X is

-NR<sup>1</sup>R<sup>2</sup> or a 4- to 10-membered mono- or polycyclic aromatic or non-aromatic ring system containing 0, 1 or 2 heteroatoms chosen from N or O and either unsubstituted or substituted with R<sup>1</sup> and R<sup>2</sup>, wherein R<sup>1</sup> and R<sup>2</sup> are independently chosen from:

- hydrogen,
- C<sub>1</sub>-6 alkyl,
- aryl C<sub>0</sub>-6 alkyl,
- carboxy C<sub>0</sub>-6 alkyl,
- hydroxy C<sub>0</sub>-6 alkyl,
- C<sub>1</sub>-3 alkyloxy C<sub>0</sub>-6 alkyl, or
- amino C<sub>0</sub>-6 alkyl;

Y is

C<sub>0</sub>-6 alkyl,  
 C<sub>1</sub>-6 alkyl-CO-C<sub>0</sub>-6 alkyl, or  
 C<sub>0</sub>-6 alkyl-NR<sup>3</sup>-CO-C<sub>0</sub>-6 alkyl, wherein R<sup>3</sup> is hydrogen,  
 C<sub>1</sub>-6 alkyl,  
 aryl C<sub>0</sub>-6 alkyl,  
 carboxy C<sub>0</sub>-6 alkyl,  
 hydroxy C<sub>0</sub>-6 alkyl,  
 C<sub>1</sub>-3 alkyloxy C<sub>0</sub>-6 alkyl, or

- 36 -

amino C0-6 alkyl;

Z is

-(CH<sub>2</sub>)<sub>m</sub>-, or -C≡C-CH<sub>2</sub>- ;

5

wherein m is 0-6;

R<sup>3</sup> is

10

hydrogen,  
C1-6 alkyl,  
aryl C0-6 alkyl,  
carboxy C0-6 alkyl,  
hydroxy C0-6 alkyl,  
C1-3 alkyloxy C0-6 alkyl, or  
amino C0-6 alkyl;

15

R<sup>7</sup> is

20

hydrogen, fluorine,  
C1-8 alkyl,  
C3-8 cycloalkyl,  
aryl C0-6 alkyl,  
C0-6 alkylamino C0-6 alkyl,  
C0-6 dialkylamino C0-6 alkyl,  
C1-8 alkylsulfonylamino C0-6 alkyl,  
aryl C0-6 alkylsulfonylamino C0-6 alkyl,  
C1-8 alkyloxycarbonylamino C0-8-alkyl,  
aryl C0-8 alkyloxycarbonylamino C0-8 alkyl,  
C1-8 alkylcarbonylamino C0-6 alkyl,  
aryl C0-6 alkylcarbonylamino C0-6 alkyl,  
C0-8 alkylaminocarbonylamino C0-6 alkyl,  
aryl C0-8 alkylaminocarbonylamino C0-6 alkyl,  
C1-6 alkylsulfonyl C0-6 alkyl,  
aryl C0-6 alkylsulfonyl C0-6 alkyl,  
C1-6 alkylcarbonyl C0-6 alkyl

25

30

- 37 -

aryl C0-6 alkylcarbonyl C0-6 alkyl,  
 C1-6 alkylthiocarbonylamino C0-6 alkyl, or  
 aryl C0-6 alkylthiocarbonylamino C0-6 alkyl wherein  
 groups may be unsubstituted or substituted with one or more  
 substituents selected from R<sup>1</sup> and R<sup>2</sup>, and provided that  
 when two R<sup>7</sup> groups are attached to the same carbon atom,  
 they may be the same or different;

R<sup>8</sup> is


hydroxy,  
 C1-6 alkyloxy,  
 aryl C1-4 alkyloxy, or  
 C1-6 alkylcarbonyloxy C1-4 alkyloxy; and

R<sup>9</sup> is

C1-3 alkyl or -W-V, wherein W is C1-3 alkyl and V is 6-  
 membered monocyclic aromatic ring system containing 0, 1,  
 2, 3 or 4 heteroatoms selected from N, O and S.

3.

A compound of Claim 2, having the formula:



wherein:

X is

-NR<sup>1</sup>R<sup>2</sup> or a 4- to 10-membered mono- or polycyclic  
 aromatic or non-aromatic ring system containing 0, 1 or 2  
 heteroatoms chosen from N or O and either

- 38 -

unsubstituted or substituted with R<sup>1</sup> and R<sup>2</sup>, wherein  
R<sup>1</sup> and R<sup>2</sup> are independently chosen from:

hydrogen,  
C<sub>1-6</sub> alkyl,  
5 aryl C<sub>0-6</sub> alkyl,  
carboxy C<sub>0-6</sub> alkyl,  
hydroxy C<sub>0-6</sub> alkyl,  
C<sub>1-3</sub> alkyloxy C<sub>0-6</sub> alkyl, or  
10 amino C<sub>0-6</sub> alkyl;

Y is

C<sub>0-6</sub> alkyl,  
C<sub>1-6</sub> alkyl-CO-C<sub>0-6</sub> alkyl, or  
15 C<sub>0-6</sub> alkyl-NR<sup>3</sup>-CO-C<sub>0-6</sub> alkyl wherein  
R<sup>3</sup> is hydrogen,  
C<sub>1-6</sub> alkyl,  
aryl C<sub>0-6</sub> alkyl,  
carboxy C<sub>0-6</sub> alkyl,  
20 hydroxy C<sub>0-6</sub> alkyl,  
C<sub>1-3</sub> alkyloxy C<sub>0-6</sub> alkyl, or  
amino C<sub>0-6</sub> alkyl;

Z is

25  $-(CH_2)_m-$ , or  $-C\equiv C-CH_2-$  ;  
wherein m is 0-3;

R<sup>3</sup> is

hydrogen,  
30 C<sub>1-6</sub> alkyl,  
aryl C<sub>0-6</sub> alkyl,  
carboxy C<sub>0-6</sub> alkyl,  
hydroxy C<sub>0-6</sub> alkyl,  
C<sub>1-3</sub> alkyloxy C<sub>0-6</sub> alkyl, or  
amino C<sub>0-6</sub> alkyl;



- 39 -

R<sup>7</sup> is

hydrogen, fluorine,

C<sub>1-8</sub> alkyl,C<sub>3-8</sub> cycloalkyl,C<sub>0-6</sub> alkylamino C<sub>0-6</sub> alkyl,C<sub>0-6</sub> dialkylamino C<sub>0-6</sub> alkyl,C<sub>1-8</sub> alkylsulfonylamino C<sub>0-6</sub> alkyl, orC<sub>1-8</sub> alkylcarbonylamino C<sub>0-6</sub> alkyl,

wherein groups may be unsubstituted or substituted with one or more substituents selected from R<sup>1</sup> and R<sup>2</sup>, and provided that when two R<sup>7</sup> groups are attached to the same carbon atom, they may be the same or different;


R<sup>8</sup> is

hydroxy,

C<sub>1-6</sub> alkyloxy,aryl C<sub>1-4</sub> alkyloxy, orC<sub>1-6</sub> alkylcarbonyloxy C<sub>1-4</sub> alkyloxy; andR<sup>9</sup> is


methyl or methylphenyl.

4. A compound of Claim 3 selected from the group of




- 40 -


5



10



15



5. A compound of Claim 1 for use in inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus formation or embolus formation, or preventing thrombus or embolus formation in a mammal.

6. A composition for inhibiting the binding of fibrinogen to blood platelets in a mammal, comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

7. A composition for inhibiting the aggregation of blood platelets in a mammal, comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

8. A composition for preventing thrombus or embolus formation in a mammal, comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

- 41 -

9. A composition for treating thrombus or embolus formation in a mammal, comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

5 10. A method for inhibiting the binding of fibrinogen to blood platelets in a mammal, comprising administering to the mammal a composition of Claim 7.

10 11. A method for inhibiting the aggregation of blood platelets in a mammal, comprising administering to the mammal the composition of Claim 7.

15 12. A method for preventing thrombus or embolus formation in a mammal, comprising administering to the mammal the composition of Claim 8.

20 13. A method for treating thrombus or embolus formation in a mammal, comprising administering to the mammal the composition of Claim 9.

25 14. A compound of Claim 4 for use in inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus formation or embolus formation, or preventing thrombus or embolus formation in a mammal.

15. A composition for inhibiting the binding of fibrinogen to blood platelets in a mammal, comprising a compound of Claim 4 and a pharmaceutically acceptable carrier.

30 16. A composition for inhibiting the aggregation of blood platelets in a mammal, comprising a compound of Claim 4 and a pharmaceutically acceptable carrier.

- 42 -

17. A composition for preventing thrombus or embolus formation in a mammal, comprising a compound of Claim 4 and a pharmaceutically acceptable carrier.

5 18. A composition for treating thrombus or embolus formation in a mammal, comprising a compound of Claim 4 and a pharmaceutically acceptable carrier.

10 19. A method for inhibiting the binding of fibrinogen to blood platelets in a mammal, comprising administering to the mammal a composition of Claim 15.

15 20. A method for inhibiting the aggregation of blood platelets in a mammal, comprising administering to the mammal the composition of Claim 16.

20 21. A method for preventing thrombus or embolus formation in a mammal, comprising administering to the mammal the composition of Claim 17.

25 22. A method for treating thrombus or embolus formation in a mammal, comprising administering to the mammal the composition of Claim 18.

30

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US94/03400

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : C07D 211/26; A61K 31/405

US CL : 540/500, 514/221

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 540/500, 514/221

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
noneElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
CAS Online

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A,4,313,947 (Nakagawa et al.) 02 February 1982, see entire document.	1-22

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be of particular relevance	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E* earlier document published on or after the international filing date	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* &	document member of the same patent family
* O* document referring to an oral disclosure, use, exhibition or other means		
* P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

14 JULY 1994

Date of mailing of the international search report

JUL 26 1994

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CATHERINE SCALZO

Telephone No. (703) 308-1235